دورية أكاديمية
أعرض في EDS

Promising antifungal activity of new oxadiazole against Candida krusei.

التفاصيل البيبلوغرافية
العنوان: Promising antifungal activity of new oxadiazole against Candida krusei.
المؤلفون: Faria DR; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil., Sakita KM; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil., Capoci IRG; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil., Arita GS; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil., Rodrigues-Vendramini FAV; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil., de Oliveira Junior AG; Department of Microbiology, Laboratory of Microbial Biotechnology, State University of Londrina, Londrina, Paraná, Brazil., Soares Felipe MS; Department of Cell Biology, Laboratory of Molecular Biology, University of Brasília, Brasília, Distrito Federal, Brazil., Bonfim de Mendonça PS; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil., Svidzinski TIE; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil., Kioshima ES; Department of Clinical Analysis and Biomedicine, Laboratory of Medical Mycology, State University of Maringá, Maringá, Paraná, Brazil.
المصدر: PloS one [PLoS One] 2020 Jan 14; Vol. 15 (1), pp. e0227876. Date of Electronic Publication: 2020 Jan 14 (Print Publication: 2020).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Antifungal Agents/*chemistry , Candida/*drug effects , Candidiasis/*drug therapy , Oxadiazoles/*chemistry, Amphotericin B/pharmacology ; Antifungal Agents/pharmacology ; Candida/pathogenicity ; Candidiasis/microbiology ; Cell Survival/drug effects ; Humans ; Macrophages/drug effects ; Oxadiazoles/pharmacology ; Stem Cells/drug effects
مستخلص: Candida krusei is one of the most common agents of invasive candidiasis and candidemia worldwide, leading to high morbidity and mortality rates. This species has become a problem due to its intrinsic resistance and reduced susceptibility to azoles and polyenes. Moreover, the number of antifungal drugs available for candidiasis treatment is limited, demonstrating the urgent need for the discovery of novel alternative therapies. In this work, the in vivo and in vitro activities of a new oxadiazole (LMM11) were evaluated against C. krusei. The minimum inhibitory concentration ranged from 32 to 64 μg/mL with a significant reduction in the colony forming unit (CFU) count (~3 log10). LMM11 showed fungicidal effect, similar to amphotericin, reducing the viable cell number (>99.9%) in the time-kill curve. Yeast cells presented morphological alterations and inactive metabolism when treated with LMM11. This compound was also effective in decreasing C. krusei replication inside and outside macrophages. A synergistic effect between fluconazole and LMM11 was observed. In vivo treatment with the new oxadiazole led to a significant reduction in CFU (0.85 log10). Furthermore, histopathological analysis of the treated group exhibited a reduction in the inflammatory area. Taken together, these results indicate that LMM11 is a promising candidate for the development of a new antifungal agent for the treatment of infections caused by resistant Candida species such as C. krusei.
Competing Interests: The authors have declared that no competing interests exist.
References: Clin Infect Dis. 2004 Jan 15;38(2):161-89. (PMID: 14699449)
Front Microbiol. 2019 Sep 12;10:2130. (PMID: 31572335)
Front Microbiol. 2015 Dec 22;6:1453. (PMID: 26733987)
Med Mycol. 2005 Mar;43(2):133-52. (PMID: 15832557)
Methods Mol Biol. 2017;1508:17-65. (PMID: 27837497)
Front Microbiol. 2016 Feb 09;7:113. (PMID: 26903992)
Med Mycol. 2017 Nov 1;55(8):859-868. (PMID: 28204571)
Mem Inst Oswaldo Cruz. 2013 May;108(3):null. (PMID: 23778668)
J Antimicrob Chemother. 2009 Jan;63(1):161-6. (PMID: 19008255)
N Engl J Med. 1991 Oct 31;325(18):1274-7. (PMID: 1669837)
Methods. 2015 Jan;71:135-45. (PMID: 25448480)
J Clin Microbiol. 2010 Apr;48(4):1366-77. (PMID: 20164282)
Rev Iberoam Micol. 2017 Jan - Mar;34(1):17-22. (PMID: 27810262)
F1000 Med Rep. 2011;3:14. (PMID: 21876720)
Braz J Microbiol. 2015 Mar 31;46(1):117-23. (PMID: 26221096)
Microb Pathog. 2017 Jun;107:390-396. (PMID: 28431915)
Med Mycol. 2012 Jan;50(1):33-42. (PMID: 21756200)
Mycoses. 2010 Nov;53(6):495-9. (PMID: 19538518)
J Glob Infect Dis. 2017 Jan-Mar;9(1):8-11. (PMID: 28250619)
PLoS One. 2016 Jan 25;11(1):e0146909. (PMID: 26808778)
J Health Econ. 2016 May;47:20-33. (PMID: 26928437)
PLoS One. 2014 Jan 22;9(1):e85836. (PMID: 24465737)
Intensive Care Med. 2014 Oct;40(10):1489-98. (PMID: 25082359)
Sci Rep. 2016 Nov 04;6:36403. (PMID: 27812015)
J Antimicrob Chemother. 2003 Jul;52(1):1. (PMID: 12805255)
J Antimicrob Chemother. 2002 Feb;49(2):345-51. (PMID: 11815578)
Cold Spring Harb Perspect Med. 2014 May 01;4(5):null. (PMID: 24789878)
Clin Microbiol Infect. 2014 Jun;20 Suppl 6:5-10. (PMID: 24506442)
Ann Intensive Care. 2016 Dec;6(1):2. (PMID: 26743881)
PLoS One. 2016 Oct 31;11(10):e0165346. (PMID: 27798663)
Expert Opin Drug Discov. 2010 Aug;5(8):739-49. (PMID: 22827797)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28652239)
PLoS One. 2015 May 19;10(5):e0126393. (PMID: 25992630)
Pharm Biol. 2017 Dec;55(1):406-415. (PMID: 27931150)
Rev Iberoam Micol. 2009 Dec 31;26(4):223-7. (PMID: 19836985)
Appl Microbiol Biotechnol. 2017 Sep;101(18):6993-7006. (PMID: 28766033)
Infect Immun. 2011 Jun;79(6):2136-44. (PMID: 21422181)
Antimicrob Agents Chemother. 2015 Nov;59(11):6975-82. (PMID: 26324281)
Indian J Med Microbiol. 2015 Jan-Mar;33(1):110-6. (PMID: 25560012)
Bone Marrow Transplant. 2015 Jan;50(1):158-60. (PMID: 25402414)
FEMS Microbiol Lett. 2011 Feb;315(2):87-93. (PMID: 21204918)
Clin Infect Dis. 2016 Feb 15;62(4):e1-50. (PMID: 26679628)
Antimicrob Agents Chemother. 1996 Aug;40(8):1914-8. (PMID: 8843303)
J Innate Immun. 2011;3(2):180-99. (PMID: 21063074)
Emerg Infect Dis. 2016 Jan;23(1):7-13. (PMID: 27983497)
FEMS Yeast Res. 2014 Nov;14(7):1068-79. (PMID: 25154541)
Front Microbiol. 2017 Mar 28;8:535. (PMID: 28400768)
Antimicrob Agents Chemother. 1997 Jun;41(6):1392-5. (PMID: 9174207)
Mycoses. 2015 Jun;58 Suppl 2:2-13. (PMID: 26033251)
Future Microbiol. 2017 Nov;12:1283-1295. (PMID: 28975802)
Antimicrob Agents Chemother. 1997 Sep;41(9):1937-9. (PMID: 9303388)
J Antimicrob Chemother. 2005 Feb;55(2):188-93. (PMID: 15650001)
Pharmacol Rev. 1995 Jun;47(2):331-85. (PMID: 7568331)
J Clin Microbiol. 2005 Sep;43(9):4434-40. (PMID: 16145088)
PLoS Negl Trop Dis. 2019 Jun 4;13(6):e0007441. (PMID: 31163021)
Folia Microbiol (Praha). 2017 Nov;62(6):525-530. (PMID: 28361459)
PLoS One. 2015 Nov 16;10(11):e0142926. (PMID: 26569405)
J Clin Microbiol. 2008 Feb;46(2):515-21. (PMID: 18077633)
mBio. 2015 Jun 23;6(3):e00647. (PMID: 26106079)
Conf Proc IEEE Eng Med Biol Soc. 2015 Aug;2015:4419-22. (PMID: 26737275)
Eur J Biochem. 2000 Oct;267(20):6102-9. (PMID: 11012661)
NPJ Biofilms Microbiomes. 2015;1:null. (PMID: 26691764)
المشرفين على المادة: 0 (Antifungal Agents)
0 (Oxadiazoles)
7XU7A7DROE (Amphotericin B)
تواريخ الأحداث: Date Created: 20200115 Date Completed: 20200416 Latest Revision: 20200416
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6959663
DOI: 10.1371/journal.pone.0227876
PMID: 31935275
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0227876